On the 24th, AIDOT announced its plan to offer its AI-powered cervical cancer system as an open AI platform, aiming to achieve innovation in cervical cancer prevention in partnership with organizations worldwide. The company stated that, by sharing its cervical cancer AI technology with colposcope manufacturers globally (colposcope: a medical device used to examine the cervix and vagina), it hopes to foster a virtuous cycle in medical AI and accelerate the global spread of Korean medical AI technology. Cerviray’s AI has already been commercialized in 13 countries over several years, achieving results in global markets. Its AI performance has been validated by clinicians in Indonesia, Mongolia, Vietnam, Mexico, Bolivia, Honduras, Kuwait, and more. Through this open platform, AIDOT expects to not only expand business models with global partners but also play a key role in securing leadership in the global cervical cancer prevention market. Jaehoon Jung, CEO of AIDOT, stated, “There has been continuous demand for Cerviray AI from manufacturers using cervical imaging devices and from medical professionals. By opening our proven cervical cancer AI engine, we expand opportunities for close cooperation with players worldwide who seek to prevent cervical cancer.” He added, “The global colposcope market was worth approximately $39.48 million in 2023 and is expected to grow at a CAGR of 4.2%. Promoting AI utilization in this global market through our technology will be a key turning point for technological innovation and advancement in this field worldwide.” To date, AIDOT’s Cerviray is the only AI worldwide able to accurately detect precise lesion locations and provide four-category lesion classification (Normal, CIN1, CIN23, Cancer) with 98% sensitivity. 

Korea Economic TV / 2025.02.24 / Senior Reporter Yang Jae-jun